Patient Groups Rate Pharma 57% Good, Pricing Concerns
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PatientView surveyed 2,400 patient groups in 35 countries from Dec 2025–Mar 2026, evaluating 47 drugmakers.
- STAT+ reported that 57% of groups rated drugmakers “excellent” or “good,” up from 56% in 2024 but still below the 60% high in 2022.
Why it matters: Patient advocacy groups gain as 57% now view drugmakers favorably, while pharma firms that fall short on patient centricity lose trust, leading to tougher pricing negotiations.
Ask SkimNews
